FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN RENEFICIAL	OWNERSH

OMB APPROVAL			
OMB Number:	3235-0287		
Estimated average burden			

0.5

hours per response

Following

(Instr. 4)

Reported Transaction(s)

600,000

(I) (Instr. 4)

D

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person' (Check all applicable) Outlook Therapeutics, Inc. [ OTLK ] Bahrt Kenneth Director Officer (give title Other (specify X below) 3. Date of Earliest Transaction (Month/Day/Year) (Last) (First) (Middle) Chief Medical Officer 02/19/2019 C/O OUTLOOK THERAPEUTICS, INC. 7 CLARKE DRIVE 6. Individual or Joint/Group Filing (Check Applicable 4. If Amendment, Date of Original Filed (Month/Day/Year) Line) (Street) X Form filed by One Reporting Person **CRANBURY** NJ 08512 Form filed by More than One Reporting (City) (State) (Qip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction Date 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 1. Title of Security (Instr. 3) 2A. Deemed Execution Date, 7. Nature of 5. Amount of 6. Ownership ు. Transaction Securities Form: Direct Indirect (Month/Day/Year) if any (Month/Day/Year) Code (Instr. Beneficially (D) or Indirect (I) (Instr. 4) Beneficial Owned Following 8) Ownership Reported (Instr. 4) Transaction(s) (Instr. 3 and 4) (A) or (D) Price Code Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of 3. Transaction 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount 8. Price of 9. Number of 10. 11. Nature Ownership Form: Derivative Security Execution Date, if any Conversion Transaction Code (Instr. of Securities Underlying Derivative Derivative Expiration Date derivative of Indirect (Month/Day/Year) (Month/Day/Year) Security or Exercise Securities Securities Beneficial Price of Derivative Acquired (A) or Disposed Derivative Sec (Instr. 3 and 4) Beneficially Owned Ownership (Instr. 4) (Instr. 3) (Month/Day/Year) 8) Security (Instr. 5) Direct (D)

## Code

02/19/2019

Explanation of Responses:

1. The shares underlying the option shall vest in four equal installments beginning on February 19, 2020 such that the option shall be vested in full on February 19, 2023, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in the event of (a) a change in control as defined in the Issuer's 2015 Equity Incentive Plan and (b) the achievement of certain predefined corporate objectives, in each case subject to the Reporting Person providing continuous service to the Issuer through such event.

Date

Exercisable

(1)

(D)

Expiration

02/19/2029

Title

Stock

Date

## Remarks:

Stock

Buy)

(Right to

Security

\$1.32

/s/ Lawrence Kenyon, Attorneyin-Fact

\$0.00

\*\* Signature of Reporting Person Date

Amount

Number

of Shares

600,000

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

of (D) (Instr. 3, 4 and 5)

(A)

600,000

ν

Α